Activated protein C resistance and the FV:R506Q mutation in a random population sample -: Associations with cardiovascular risk factors and coagulation variables

被引:0
|
作者
Lowe, GDO
Rumley, A
Woodward, M
Reid, E
Rumley, J
机构
[1] Univ Glasgow, Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Reading, Dept Appl Stat, Reading RG6 2AH, Berks, England
[3] Univ Glasgow, Yorkhill Hosp, Dept Med Genet, Glasgow, Lanark, Scotland
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activated protein C (APC) resistance, defined as a low APC ratio, is associated with the factor V mutation R(506)Q (factor V Leiden). APC ratio map also be influenced by other clinical and coagulation variables, which we studied in 460 men and 495 women aged 25-74 years, from a random population sample (Glasgow MONICA Survey). APC ratio correlated positively with APTT; and inversely with factor VIIIc, factor IXc, antithrombin activity, prothrombin F1+2 fragment, and thrombin-antithrombin complexes; but not with other coagulation variables. APC ratio decreased with age, but APTT did not. APC ratio and APTT were significantly lower in women versus men? and were significantly lower in users of oral contraceptives or hormone replacement therapy. The EV:R(506)Q mutation (prevalence 2.5%) was associated with lower APC ratio and protein C and S activities and with higher factor VIIIc levels; but not with increases in F1+2 fragment or thrombin-antithrombin complexes. APC ratio correlated inversely with total cholesterol and di astolic blood pressure; and in women with triglycerides, systolic blood pressure, and body mass index. Obesity was associated with a significantly lower APC ratio. In contrast, smoking markers correlated positively with APC ratio in men. These associations of APC ratio may be relevant to the increased risks of venous thrombosis with age, female sex, oestrogen use,obesity and high factor VIIIc levels. The association of APC resistance with elevated plasma levels of coagulation markers suggests that this phenotype represents an in vivo hypercoagulable state.
引用
收藏
页码:918 / 924
页数:7
相关论文
共 50 条
  • [21] Clinical and biological data in 85 R506Q homozygotes. French register on activated protein C resistance (APCR): PROCARE Study
    Biron, C
    Schved, JF
    Aillaud, MF
    Juhan, I
    Bauters, A
    Jude, B
    Pernod, G
    Polack, B
    Bridey, F
    deProst, D
    Borg, JY
    Saladin, C
    Lecam, V
    Denninger, MH
    Truchaud, F
    Trossaert, M
    Boinot, C
    Sultan, Y
    Delahousse, B
    Fimbel, B
    Gruel, Y
    Houbouyan, L
    Bihour, C
    Vergnes, C
    Dutrillaux, F
    Lorenzini, JL
    Julia, A
    Deschamps, A
    Favier, R
    Freyburger, G
    Treziack, MC
    Berruyer, M
    Gris, JC
    Toulon, P
    MarquesVerdier, A
    Lequerrec, A
    Guerin, V
    Massignon, D
    BLOOD, 1997, 90 (10) : 654 - 654
  • [22] Inherited resistance to activated protein C caused by presence of the FV:Q(506) allele as a basis of venous thrombosis
    Dahlback, B
    Zoller, B
    Hillarp, A
    HAEMOSTASIS, 1996, 26 : 301 - 314
  • [23] Factor V R506Q gene mutation analysis by PCR-RFLP - Optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls
    Voelkerding, KV
    Wu, L
    Williams, EC
    Hoffman, SM
    Sabatini, LM
    Borcherding, WR
    Huber, S
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 106 (01) : 100 - 106
  • [24] Increased resistance of platelet-derived factor Va(R506Q) to inactivation by activated protein C on the surface of alpha-thrombin activated platelets.
    Kalafatis, M
    Camire, RM
    Simioni, P
    Girolami, A
    Tracy, PB
    Mann, KG
    BLOOD, 1995, 86 (10) : 792 - 792
  • [25] The VITA Project: Phenotypic resistance to activated protein C and FV Leiden mutation in the general population
    Tosetto, A
    Missiaglia, E
    Gatto, E
    Rodeghiero, F
    THROMBOSIS AND HAEMOSTASIS, 1997, 78 (02) : 859 - 863
  • [26] The predictability of factor V Leiden (FV:Q506) gene mutation via clotting-based diagnosis of activated protein C resistance
    Sayinalp, N
    Haznedaroglu, IC
    Aksu, S
    Büyükasik, Y
    Göker, H
    Parlak, H
    Özcebe, OI
    Kirazli, S
    Dündar, SV
    Gürgey, A
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (03) : 265 - 270
  • [27] A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation
    Prueller, Florian
    Raggam, Reinhard B.
    Mangge, Harald
    Truschnig-Wilders, Martie
    Matzhold, Eva-Maria
    Weiss, Eva-Christine
    Hasiba, Barbara
    Summers, Kelli L.
    Renner, Wilfried
    Siegert, Gabriele
    Kostka, Heike
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (03) : 414 - 417
  • [28] Activated protein C resistance and Q506 mutation of factor V in venous thromboembolism.
    Garcin, JM
    Plotton, N
    Collet, JP
    AlhencGelas, M
    Emmerich, J
    Chanudet, X
    Larroque, P
    SEMAINE DES HOPITAUX, 1997, 73 (25-26): : 793 - 799
  • [29] Acquired activated protein C resistance in patients with thrombosis without the factor V Q (506) mutation
    Eikelboom, J
    Ivey, L
    Thom, J
    Ivey, J
    Baker, R
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1305 - P1305
  • [30] The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients
    Prazanowski, M
    Kur, B
    Baranska, M
    Lutz, W
    Pilacik, B
    Kolacinski, Z
    CLINICAL TOXICOLOGY, 2006, 44 (01) : 52 - 56